Previous 10 | Next 10 |
Leap Therapeutics Announces Completion of Enrollment for First-Line Patient Cohort in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer PR Newswire CAMBRIDGE, Mass. , April 1, 2021 /PRNewswire/ -- Le...
Frequency Therapeutics (FREQ) -71% after releases new data. from two FX-322 clinical studies; plans to advance single-dose regimen.Anixa Biosciences (ANIX) -23% after raises previously announced bought deal offering of common stock to $22.5M.Windtree Therapeutics (WIN...
Some Of The Best Penny Stocks To Watch Early This Week This week has started stronger than the last & we have plenty of trending penny stocks to watch as a result. Last week the markets sold off, with tech continuing its move lower. What’s more, over the weekend, new virus da...
Leap Therapeutics (LPTX) shares up more than 13% premarket after posting positive data from its Phase 2 clinical trial of DKN-01 as a monotherapy and in combination with paclitaxel in patients with advanced gynecological malignancies.The P204 study was a Phase 2 basket study evaluat...
Support.com (SPRT) +271% as Greenidge Generation Holdings to go public via merger with the company.Seneca Biopharma (SNCA) +30%.Cemtrex (CETX) +21%.Marker Therapeutics (MRKR) +19%.Acer Therapeutics (ACER) +19%.Kansas City Southern (KSU) +17% as Canadian Pacific to buy the company fo...
Leap Therapeutics Presents DKN-01 Clinical Data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer - DKN-01 Monotherapy Demonstrated Clinical Activity in Patients with Endometrial Cancer - Tumoral DKK1 Expression Biomarker Predicts Strongest Outcome...
Leap Therapeutics (LPTX): Q4 GAAP EPS of -$0.09 in-line.Revenue of $0.38M misses by $0.01M.Press Release For further details see: Leap Therapeutics EPS in-line, misses on revenue
Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results PR Newswire CAMBRIDGE, Mass. , March 12, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology ther...
Leap Therapeutics to Present at Upcoming Virtual Investor Conferences PR Newswire CAMBRIDGE, Mass. , Feb. 22, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics,...
Leap Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference PR Newswire CAMBRIDGE, Mass. , Jan. 6, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...
News, Short Squeeze, Breakout and More Instantly...
Leap Therapeutics Inc. Company Name:
LPTX Stock Symbol:
NASDAQ Market:
Leap Therapeutics Inc. Website:
Leap Therapeutics Reports First Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today report...
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...